Benzinga | Feb 17, 2021 09:04AM EST

Natera And Personalis Announce Personalized Oncology Partnership

SAN CARLOS, Calif. and MENLO PARK, Calif., Feb. 17, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, and Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the two companies have entered into a partnership in the field of personalized oncology. The partnership will pair Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera(tm) for treatment monitoring and molecular residual disease (MRD) assessment.

Under this non-exclusive agreement, Natera will validate the design of Signatera personalized ctDNA assays using matched tumor and normal exome sequence data from Personalis, and Natera will be responsible for commercialization. The agreement covers MRD testing for both clinical use and research use.